Status:
TERMINATED
Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml
Lead Sponsor:
Hospital Clinica Nova
Conditions:
Covid19
Influenza A
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Scarce information exists in relation to the effect of supplementation of Vitamin D3 in SARS-COV-2 infection, H1N1, and A, B Influenza when 25-hydroxyvitamin levels are between 20-100ng/ml. This study...
Detailed Description
COVID-19 is an infectious disease caused by the newly discovered coronavirus SARS-CoV-2, with a clinical spectrum from asymptomatic infection to critical and fatal illnesses. Influenza H1N1, A, and B ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age 18-90 years
- Both genders
- Absence of infection by COVID-19, influenza H1N1, influenza A or B at the time of measurement of serum vitamin D levels.
- Absence of infection at any site of bacterial, fungal or other origins
- Health worker at Hospital Clínica Nova.
- Patient Exclusion Criteria for both arms:
- Serum Vitamin D levels\> 100ng / ml
- Previous consumption of supplements containing Vitamin D3
- Pregnancy
Exclusion
Key Trial Info
Start Date :
August 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2021
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT04810949
Start Date
August 5 2020
End Date
March 1 2021
Last Update
April 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clinica Nova de Monterrey
San Nicolás de los Garza, Nuevo León, Mexico, 66450